|
1
|
Keith RL and Miller YE: Lung cancer
chemoprevention: Current status and future prospects. Nat Rev Clin
Oncol. 10:334–343. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blackhall FH, Shepherd FA and Albain KS:
Improving survival and reducing toxicity with chemotherapy in
advanced non-small cell lung cancer: A realistic goal? Treat Respir
Med. 4:71–84. 2005. View Article : Google Scholar
|
|
3
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75(Suppl): 191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mosesson Y and Yarden Y: Oncogenic growth
factor receptors: Implications for signal transduction therapy.
Semin Cancer Biol. 14:262–270. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohsaki Y, Tanno S, Fujita Y, Toyoshima E,
Fujiuchi S, Nishigaki Y, Ishida S, Nagase A, Miyokawa N, Hirata S,
et al: Epidermal growth factor receptor expression correlates with
poor prognosis in non-small cell lung cancer patients with p53
overexpression. Oncol Rep. 7:603–607. 2000.PubMed/NCBI
|
|
6
|
Inamura K, Ninomiya H, Ishikawa Y and
Matsubara O: Is the epidermal growth factor receptor status in lung
cancers reflected in clinicopathologic features? Arch Pathol Lab
Med. 134:66–72. 2010.PubMed/NCBI
|
|
7
|
Siveen KS, Nguyen AH, Lee JH, Li F, Singh
SS, Kumar AP, Low G, Jha S, Tergaonkar V, Ahn KS, et al: Negative
regulation of signal transducer and activator of transcription-3
signalling cascade by lupeol inhibits growth and induces apoptosis
in hepatocellular carcinoma cells. Br J Cancer. 111:1327–1337.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scagliotti GV, Selvaggi G, Novello S and
Hirsch FR: The biology of epidermal growth factor receptor in lung
cancer. Clin Cancer Res. 10:S4227–S4232. 2004. View Article : Google Scholar
|
|
9
|
Veale D, Kerr N, Gibson GJ, Kelly PJ,
Harris AL and Br J: The relationship of quantitative epidermal
growth factor receptor expression in non-small cell lung cancer to
long term survival. Br J Cancer. 68:162–165. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fontanini G, De Laurentiis M, Vignati S,
Chinè S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G,
Bianco AR, et al: Evaluation of epidermal growth factor-related
growth factors and receptors and of neoangiogenesis in completely
resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and
microvessel count are independent prognostic indicators of
survival. Clin Cancer Res. 4:241–249. 1998.PubMed/NCBI
|
|
11
|
Ogawa J, Iwazaki M, Inoue H, Koide S and
Shohtsu A: Immunohistochemical study of glutathione-related enzymes
and proliferative antigens in lung cancer. Relation to cisplatin
sensitivity. Cancer. 71:2204–2209. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar
|
|
13
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from 'never
smokers' and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar
|
|
16
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnston PA and Grandis JR: STAT3
signaling: Anticancer strategies and challenges. Mol Interv.
11:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Harada D, Takigawa N and Kiura K: The role
of STAT3 in non-small cell lung cancer. Cancers (Basel). 6:708–722.
2014. View Article : Google Scholar
|
|
20
|
Jiang R, Jin Z, Liu Z, Sun L, Wang L and
Li K: Correlation of activated STAT3 expression with
clinicopathologic features in lung adenocarcinoma and squamous cell
carcinoma. Mol Diagn Ther. 15:347–352. 2011. View Article : Google Scholar
|
|
21
|
Xu YH and Lu S: A meta-analysis of STAT3
and phospho-STAT3 expression and survival of patients with
non-small-cell lung cancer. Eur J Surg Oncol. 40:311–317. 2014.
View Article : Google Scholar
|
|
22
|
Gao SP, Chang Q, Mao N, Daly LA, Vogel R,
Chan T, Liu SH, Bournazou E, Schori E, Zhang H, et al: JAK2
inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to
tyrosine kinase inhibitors. Sci Signal. 9:ra332016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yao Z, Fenoglio S, Gao DC, Camiolo M,
Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V,
et al: TGF-beta IL-6 axis mediates selective and adaptive
mechanisms of resistance to molecular targeted therapy in lung
cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK,
Sica GL, Ramalingam SS, Curran WJ, Khuri FR and Deng X: Niclosamide
overcomes acquired resistance to erlotinib through suppression of
STAT3 in non-small cell lung cancer. Mol Cancer Ther. 12:2200–2212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB,
Ko YG, Lee JS, Lee SJ, Lee JC and Park MJ: Upregulation of CXCR4 is
functionally crucial for maintenance of stemness in drug-resistant
non-small cell lung cancer cells. Oncogene. 32:209–221. 2013.
View Article : Google Scholar
|
|
26
|
Fan W, Tang Z, Yin L, Morrison B,
Hafez-Khayyata S, Fu P, Huang H, Bagai R, Jiang S, Kresak A, et al:
MET-independent lung cancer cells evading EGFR kinase inhibitors
are therapeutically susceptible to BH3 mimetic agents. Cancer Res.
71:4494–4505. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zulkifli AA, Tan FH, Putoczki TL, Stylli
SS and Luwor RB: STAT3 signaling mediates tumour resistance to EGFR
targeted therapeutics. Mol Cell Endocrinol. 451:15–23. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Siddique HR and Saleem M: Beneficial
health effects of lupeol triterpene: A review of preclinical
studies. Life Sci. 88:285–293. 2011. View Article : Google Scholar
|
|
29
|
Wu XT, Liu JQ, Lu XT, Chen FX, Zhou ZH,
Wang T, Zhu SP and Fei SJ: The enhanced effect of lupeol on the
destruction of gastric cancer cells by NK cells. Int
Immunopharmacol. 16:332–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G
and Gao Q: Lupeol enhances inhibitory effect of 5-fluorouracil on
human gastric carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol.
389:477–484. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tarapore RS, Siddiqui IA, Adhami VM,
Spiegelman VS and Mukhtar H: The dietary terpene lupeol targets
colorectal cancer cells with constitutively active Wnt/β-catenin
signaling. Mol Nutr Food Res. 57:1950–1958. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pitchai D, Roy A and Ignatius C: In vitro
evaluation of anticancer potentials of lupeol isolated from
Elephantopus scaber L. on MCF-7 cell line. J Adv Pharm Technol Res.
5:179–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sankaranarayanan S, Bama P, Sathyabama S
and Bhuvaneswari N: Anticancer compound isolated from the leaves of
Tridax procumbens against human lung cancer cell A-549. Asian J
Pharm Clin Res. 6:91–96. 2013.
|
|
34
|
He W, Li X and Xia S: Lupeol triterpene
exhibits potent antitumor effects in A427 human lung carcinoma
cells via mitochondrial mediated apoptosis, ROS generation, loss of
mitochondrial membrane potential and downregulation of
m-TOR/PI3Ksol;AKT signalling pathway. J BUON. 23:635–640.
2018.PubMed/NCBI
|
|
35
|
Lee TK, Castilho A, Cheung VC, Tang KH, Ma
S and Ng IO: Lupeol targets liver tumor-initiating cells through
phosphatase and tensin homolog modulation. Hepatology. 53:160–170.
2011. View Article : Google Scholar
|
|
36
|
Liu Y, Bi T, Shen G, Li Z, Wu G, Wang Z,
Qian L and Gao Q: Lupeol induces apoptosis and inhibits invasion in
gallbladder carcinoma GBC-SD cells by suppression of EGFR/MMP-9
signaling pathway. Cytotechnology. 68:123–133. 2016. View Article : Google Scholar :
|
|
37
|
Rauth S, Ray S, Bhattacharyya S, Mehrotra
DG, Alam N, Mondal G, Nath P, Roy A, Biswas J and Murmu N: Lupeol
evokes anticancer effects in oral squamous cell carcinoma by
inhibiting oncogenic EGFR pathway. Mol Cell Biochem. 417:97–110.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grosdidier A, Zoete V and Michielin O:
SwissDock, a protein-small molecule docking web service based on
EADock DSS. Nucleic Acids Res. 39(Suppl): W270–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Berman HM, Westbrook J, Feng Z, Gilliland
G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE: The protein
data bank. Nucleic Acids Res. 28:235–242. 2000. View Article : Google Scholar
|
|
40
|
Choowongkomon K, Sawatdichaikul O,
Songtawee N and Limtrakul J: Receptor-based virtual screening of
EGFR kinase inhibitors from the NCI diversity database. Molecules.
15:4041–4054. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stamos J, Sliwkowski MX and Eigenbrot C:
Structure of the epidermal growth factor receptor kinase domain
alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol
Chem. 277:46265–46272. 2002. View Article : Google Scholar : PubMed/NCBI
|
